Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
FERRETTI, Antonio Christian,MAN, Hon Wah,MUSLEHIDDINOGLU, Jale,XU, Jean,YONG, Kelvin Hin-yeong,KOTHARE, Mohit Atul,ZHOU, Nanfei,BEAUCHAMPS, Marie Georges,BOERSEN, Nathan Andrew,LI, Ying,HILGRAF, Rober
申请号：
AU2020202146
公开号：
AU2020202146A1
申请日:
2020.03.26
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2020202146A120200416.pdf#####ABSTRACT Provided herein are formulations, processes, solid forms and methods of use relating to 2(tert-butylamino)-4-((1R,3R,4R)-3- hydroxy-4-methylcydohexylamino)-pyrimidine-5-carboxamide (Compound I). In another aspect, provided herein are methods for preparing certain compounds, including Compound I as described herein, as well as intermediates useful in such methods. In certain aspects, the solid forms of Compound I are useful for inhibiting a kinase in a cell expressing said kinase, for example JNK1 or JNK2. In another aspect, the solid forms of Compound I are useful for treating or preventing one or more disorders selected from interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody mediated rejection, or lupus.
